← Leaderboards
Han-Xiang Deng
Northwestern University
$10,076,503
Attributed
$10,076,503
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,076,503 · 9
By mechanism
R01$7,964,074 · 4
R21$2,112,429 · 5
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Mutation”
- Richard A Gibbs · Baylor College Of Medicine$276,143,183
- David Heimbrook · Leidos Biomedical Research, Inc.$175,834,894
- Randall J Bateman · Washington University$154,391,630
- Eric Martin McDade · Washington University$96,219,353
- Stacey Gabriel · Massachusetts Institute Of Technology$95,141,374
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$93,475,056
Research focus
MutationLinkGenesDesignPathologyMouse ModelPhenotypeFamilyTransgenic MicePathogenesisGeneticAffectBaseMolecularAmyotrophic Lateral SclerosisBiochemicalMutantResourcesMemberDefectSamplingMapsPathologicAmerican
Grant awards (29)
Mouse model studies of TMEM230-linked Parkinson's disease$450,079
R01 · FY2025 · NS · contact PI
Mouse model studies of TMEM230-linked Parkinson's disease$485,086
R01 · FY2024 · NS · contact PI
Mouse model studies of TMEM230-linked Parkinson's disease$500,086
R01 · FY2023 · NS · contact PI
Mouse model studies of TMEM230-linked Parkinson's disease$518,815
R01 · FY2022 · NS · contact PI
Development of a novel therapeutic strategy for treatment of SOD1-linked ALS by CRISPR/Cas9-mediated SOD1 promoter editing$376,000
R01 · FY2022 · NS · contact PI
Development of a novel therapeutic strategy for treatment of SOD1-linked ALS by CRISPR/Cas9-mediated SOD1 promoter editing$374,825
R01 · FY2021 · NS · contact PI
Mouse model studies of TMEM230-linked Parkinson's disease$442,758
R01 · FY2020 · NS · contact PI
Development of CHCHD2-linked PD mouse models$434,500
R21 · FY2020 · NS · contact PI
Development of a novel therapeutic strategy for treatment of SOD1-linked ALS by CRISPR/Cas9-mediated SOD1 promoter editing$371,300
R01 · FY2020 · NS · contact PI
Mouse model studies of TMEM230-linked Parkinson's disease$442,758
R01 · FY2019 · NS · contact PI
Mouse model studies of TMEM230-linked Parkinson's disease$442,758
R01 · FY2018 · NS · contact PI
Mouse model studies of TMEM230-linked Parkinson's disease$442,758
R01 · FY2017 · NS · contact PI
Development of mouse models for ALS5 and SPG11$193,125
R21 · FY2017 · NS · contact PI
Mouse model studies of TMEM230-linked Parkinson's disease$460,656
R01 · FY2016 · NS · contact PI
Development of mouse models for ALS5 and SPG11$231,750
R21 · FY2016 · NS · contact PI
Molecular basis of Scapuloperoneal SMA and Charcot-Marie-Tooth disease type 2C$337,969
R01 · FY2015 · NS · contact PI
Molecular basis of Scapuloperoneal SMA and Charcot-Marie-Tooth disease type 2C$334,590
R01 · FY2014 · NS · contact PI
Molecular basis of Scapuloperoneal SMA and Charcot-Marie-Tooth disease type 2C$326,140
R01 · FY2013 · NS · contact PI
Development of mouse models of optineurin-linked ALS$186,366
R21 · FY2013 · NS · contact PI
Molecular basis of Scapuloperoneal SMA and Charcot-Marie-Tooth disease type 2C$337,969
R01 · FY2012 · NS · contact PI
Development of mouse models of optineurin-linked ALS$231,750
R21 · FY2012 · NS · contact PI
Identification of a Novel Gene for Parkinson Disease$228,750
R21 · FY2012 · NS · contact PI
Identification of a Novel Gene for Parkinson Disease$190,625
R21 · FY2011 · NS · contact PI
Transgenic Study of ALS-Linked CCS Mutations$186,813
R21 · FY2011 · NS · contact PI
Transgenic Study of ALS-Linked CCS Mutations$228,750
R21 · FY2010 · NS · contact PI
TRANSGENIC STUDIES OF AMYOTROPHIC LATERAL SCLEROSIS$330,750
R01 · FY2004 · NS
TRANSGENIC STUDIES OF AMYOTROPHIC LATERAL SCLEROSIS$330,750
R01 · FY2003 · NS
TRANSGENIC STUDIES OF AMYOTROPHIC LATERAL SCLEROSIS$330,750
R01 · FY2002 · NS
TRANSGENIC STUDIES OF AMYOTROPHIC LATERAL SCLEROSIS$327,277
R01 · FY2001 · NS